Видео ютуба по тегу William G Wierda Md Phd

Meet leukemia oncologist William Wierda, M.D., Ph.D.
Meet leukemia oncologist William Wierda, M.D., Ph.D.
Dr. Wierda on Diagnosing Chronic Lymphocytic Leukemia
Dr. Wierda on Diagnosing Chronic Lymphocytic Leukemia
Dr. Wierda on Frontline Management of Patients With CLL
Dr. Wierda on Frontline Management of Patients With CLL
Dr. Wierda on Treating CLL with 17p Deletion
Dr. Wierda on Treating CLL with 17p Deletion
Dr. William G. Wierda on Role for Ibrutinib in Frontline CLL
Dr. William G. Wierda on Role for Ibrutinib in Frontline CLL
Dr. Wierda Discusses the CLL11 Trial
Dr. Wierda Discusses the CLL11 Trial
The High Risk Patient
The High Risk Patient
Dr. Wierda on Treatment Recommendations for Elderly Patients With CLL
Dr. Wierda on Treatment Recommendations for Elderly Patients With CLL
Advances in the treatment of chronic lymphocytic leukemia
Advances in the treatment of chronic lymphocytic leukemia
CLL Society Ed Forum: ASH 2020 Comes to You - William Wierda, MD, PhD
CLL Society Ed Forum: ASH 2020 Comes to You - William Wierda, MD, PhD
Reverse Inhibitors?
Reverse Inhibitors?
Dr. Wierda on Immunotherapy Agents for Patients With CLL
Dr. Wierda on Immunotherapy Agents for Patients With CLL
Importance of prognostic factors in the treatment of CLL and how to assess them
Importance of prognostic factors in the treatment of CLL and how to assess them
Dr. Wierda on Role of Rituximab Biosimilar in Evolving CLL Treatment Paradigm
Dr. Wierda on Role of Rituximab Biosimilar in Evolving CLL Treatment Paradigm
Important prognostic factors to evaluate in CLL patients in the era of small molecules
Important prognostic factors to evaluate in CLL patients in the era of small molecules
Accelerated Pace of Advancements
Accelerated Pace of Advancements
Highlights from iwCLL 2019: MRD and novel therapies
Highlights from iwCLL 2019: MRD and novel therapies